Kadcyla 160 mg/vial (IV Infusion)

Indications

• Metastatic Breast Cancer (MBC): Kadcyla is indicated for the treatment of patients with HER2-positive, unresectable locally advanced or metastatic breast cancer who have received prior treatment with trastuzumab and a taxane.

Pharmacology

• Trastuzumab Emtansine is a HER2-targeted antibody-drug conjugate which contains the humanized anti-HER2 IgG1, trastuzumab, covalently linked to the microtubule inhibitory drug DM1 via the stable thioether linker MCC.

Dosage & Administration

• Recommended dose of 3.6 mg/kg given as an intravenous infusion every 3 weeks (21-day cycle) until disease progression or unacceptable toxicity.

Interaction

• No formal drug-drug interaction studies with Kadcyla in humans have been conducted.

Contraindications

• Trastuzumab Emtansine is contraindicated in patients with a known hypersensitivity to Trastuzumab Emtansine or any of its excipients.

Pregnancy & Lactation

• No clinical studies of trastuzumab emtansine in pregnant women.

Precautions & Warnings

• Patients treated with Kadcyla must have confirmed HER2-positive tumor status as assessed by either HER2 protein overexpression or gene amplification.

Use in Special Populations

• The safety and efficacy of Kadcyla in children below 18 years of age have not been established.

Therapeutic Class

• Anti neoplastic preparations

Storage Conditions

• Store vials at 2°C-8°C.

Related Brands

• Kadcyla 100 mg/vial (IV Infusion) - roche-bangladesh-ltd